Crucial gaps in knowledge prevent the providing of ideal individualized care to women with endometrial cancer. The extent of lymphadenectomy and the identification of which patients would benefit the most from complete surgical staging are unresolved clinical issues. A second important gap is the ability to predict which women with low stage endometrioid-type endometrial cancer will suffer recurrence. We have used genomic approaches to identify tissue biomarkers of endometrial cancer. These biomarkers have been validated in a large set of endometrial cancers at MDACC, and we have documented their close association with stage and recurrence. Next, we will validate these findings in independent data sets. We hypothesize that quantifying genes associated with EMT and estrogen's growth regulatory actions in the endometrium as a """"""""biomarker score"""""""" will provide a clinically useful tool to assist in the decision to perform complete surgical staging on women diagnosed with endometrial cancer and will predict which women with stage I and stage II endometrioid carcinomas will recur.
In Aim 1, we will validate the association of our biomarkers with endometrial cancer stage in an independent data set obtained from a series of patients who unden/vent comprehensive surgical staging at the Mayo clinic. We will also establish that the biomarker score computed from formalin-fixed, paraffin-embedded endometrial biopsies is a good approximation of the same scores based on tissue from the final hysterectomy. We will determine the association of the biomarker panel with endometrioid carcinoma recurrence in independent data sets obtained from Mayo Clinic and Washington University.
In Aim 2, reverse phase protein lysate array (RPPA) will be used to identify proteins and phospho-proteins that are associated with endometrioid carcinoma stage. These newly identified biomarkers will be used to augment our currently existing panel. We will also develop methodology to perform RPPA using formalin-fixed tissues so that this technology becomes more relevant to clinical samples. Finally RPPA will be used to help identify proteins that interact with EIG121, one of the more exciting but least understood biomarkers in our existing panel.
Currently, we cannot reliably identify pre-operatively the endometrial cancer patients who would benefit most from extensive surgical staging. In addition, we cannot reliably predict the women with low stage endometrioid-type endometrial cancer who will suffer recurrence. We propose here to validate and augment a biomarker panel that can help to better individualize endometrial cancer patient care.
|Du, Di; Ma, Wencai; Yates, Melinda S et al. (2018) Predicting high-risk endometrioid carcinomas using proteins. Oncotarget 9:19704-19715|
|Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8|
|Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15|
|Kim, Grace; Kurnit, Katherine C; Djordjevic, Bojana et al. (2018) Nuclear ?-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol 31:1553-1559|
|Yoo, Jung-Yoon; Kang, Hee-Bum; Broaddus, Russell R et al. (2018) MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer 18:605|
|Yuan, Ying; Lin, Ruitao; Li, Daniel et al. (2018) Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24:4921-4930|
|Yates, Melinda S; Coletta, Adriana M; Zhang, Qian et al. (2018) Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila) 11:477-490|
|Yan, F; Thall, P F; Lu, K H et al. (2018) Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol 29:694-699|
|Gao, Chao; Wang, Yingmei; Broaddus, Russell et al. (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 9:5492-5508|
|Pan, Haitao; Liu, Suyu; Miao, Danmin et al. (2018) Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18:32|
Showing the most recent 10 out of 578 publications